

## POST-TEST

### Expert Second Opinion: Investigators Discuss the Optimal Management of HER2-Positive Gastrointestinal Cancers

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What was the approximate objective response rate observed with trastuzumab deruxtecan in patients with previously treated HER2 IHC 3+ advanced biliary tract cancer (BTC) in the Phase II DESTINY-PanTumor02 trial?
  - a. 0%
  - b. 18%
  - c. 32%
  - d. 56%
2. The Phase IIb HERIZON-BTC-01 trial evaluating zanidatamab in patients with previously treated unresectable, locally advanced or metastatic BTC that is HER2 positive reported which of the following as the most common adverse effect?
  - a. Cytokine release syndrome
  - b. Diarrhea
  - c. Infusion-related reactions
  - d. Left ventricular dysfunction
3. Which of the following best describes the experimental treatment arm that is being compared to first-line trastuzumab/pembrolizumab/fluoropyrimidine/platinum in the main cohort of Phase III DESTINY-Gastric05 study?
  - a. T-DXd monotherapy
  - b. T-DXd/durvalumab
  - c. T-DXd/durvalumab/fluoropyrimidine
  - d. T-DXd/pembrolizumab
  - e. T-DXd/pembrolizumab/fluoropyrimidine
4. Recent data from the Phase III HERIZON-GEA-01 trial comparing zanidatamab and chemotherapy with or without tislelizumab to trastuzumab and chemotherapy as first-line treatment for metastatic HER2-positive gastroesophageal adenocarcinoma indicate which of the following observations?
  - a. Only zanidatamab with tislelizumab and chemotherapy demonstrated a statistically significant improvement in progression-free survival (PFS)
  - b. Only zanidatamab with chemotherapy demonstrated a statistically significant improvement in PFS
  - c. Both zanidatamab with chemotherapy and zanidatamab with tislelizumab and chemotherapy demonstrated statistically significant improvements in PFS
  - d. Neither experimental study arm demonstrated a statistically significant improvement in PFS
5. What was the approximate objective response rate observed with trastuzumab deruxtecan in patients with previously treated HER2 IHC 3+ or IHC 2+/ISH+ unresectable and/or metastatic colorectal cancer in the Phase II DESTINY-CRC01 trial?
  - a. 0%
  - b. 24%
  - c. 45%
  - d. 60%